Texas · J1306

Injection, Inclisiran, 1 Mg in Texas

Texas Medicare Avg
$9.38
0% above national avg
National Medicare Avg
$9.36
All states combined
Billed Charge (TX)
$36.03
What providers submit
Est. Commercial (TX)
$27.15
National avg: $26.40
Est. Cash / Self-Pay (TX)
$18.76
Typical self-pay discount

Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.

803.1K
Services in TX
227
Providers
N/A
Min Payment
N/A
Max Payment

Top Providers in Texas

Provider Medicare Services
Prewett, Wendy $9.37 100.8K
Hampton, Julie FNP-C $9.36 46.0K
Shepherd, Tricia $9.40 41.2K
Amurawaiye, Busola FNP-C $9.40 25.0K
Khan, Nasira PA-C $9.39 24.4K
Kone, Makaba FNP-C $9.39 24.4K
Francesconi, James MD $9.36 20.7K
Tan, Filemon M.D. $9.38 20.4K
Campbell, Lisa FNP-BC $9.33 18.5K
Click, Morgan FNP-C $9.39 18.2K
Alford, Irene MSN APRN FNP-C $9.36 17.9K
Benitez, Saul ACNS $9.41 13.6K
Summers, Kevin $9.42 13.3K
Price, Todd M.D. $9.39 12.8K
Stolfa, Carrie NP $9.36 11.4K
Marpu, Niharika M.D. $9.39 9.9K
Robledo, Shanna FNP $9.38 9.7K

Texas Pricing in Context

In Texas, CPT code J1306 (Injection, Inclisiran, 1 Mg) carries an average Medicare payment of $9.38 — 0% above the national benchmark of $9.36. 227 providers across the state submitted claims for this procedure in 2023, performing 803.1K total services. Individual payments in TX ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.

The average billed charge in Texas is $36.03, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because Texas sits above the national Medicare average, commercial rates in the state may also run higher than the US median.

Using RAND 2024 commercial-to-Medicare ratios for Drugs (Administered) procedures, the estimated commercial insurance price in Texas lands near $27.15, with self-pay cash prices typically around $18.76. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.

Frequently Asked Questions

How much does Injection, Inclisiran, 1 Mg cost in Texas?

The average Medicare payment for Injection, Inclisiran, 1 Mg in Texas is $9.38, which is 0% above the national average of $9.36. Providers in TX typically bill $36.03 for this procedure.

What does Injection, Inclisiran, 1 Mg cost with insurance in Texas?

With commercial insurance in Texas, Injection, Inclisiran, 1 Mg costs an estimated $27.15. Without insurance, the estimated cash price is $18.76. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.

How many providers perform Injection, Inclisiran, 1 Mg in Texas?

227 providers in Texas billed Medicare for Injection, Inclisiran, 1 Mg in 2023, performing 803.1K total services. Medicare payments ranged from N/A to N/A depending on the provider.

Is Injection, Inclisiran, 1 Mg cheaper in Texas than the national average?

No — Injection, Inclisiran, 1 Mg costs 0% above the national average in Texas. The state average Medicare payment is $9.38 compared to $9.36 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.

Related

Data sourced from the CMS Medicare Physician and Other Practitioners dataset. See our methodology for details. Retrieved and formatted by PlainProcedure Editorial